BeiGene Ltd logo

BeiGene Ltd - ADR

1
NAS:BGNE (Cayman Islands)   ADR
$ 168.78 -1.5 (-0.88%) 07:08 PM EST
At Loss
P/B:
4.98
Market Cap:
$ 18.62B
Enterprise V:
$ 16.47B
Volume:
148.23K
Avg Vol (2M):
305.93K
Also Trade In:
Volume:
148.23K
At Loss
Avg Vol (2M):
305.93K

Business Description

Description
BeiGene Ltd is a commercial-stage biotechnology company. It is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The company has developed a proprietary cancer biology platform that addresses the importance of tumor-immune system interactions and the value of primary biopsies in developing new models to support its drug discovery effort. It has developed clinical-stage drug candidates that inhibit the important oncology targets Bruton's tyrosine kinase, or BTK; RAF dimer protein complex and PARP family of proteins, and an immuno-oncology agent that inhibits the immune checkpoint protein receptor PD-1. Its geographical segments are China, the United States, and the Rest of the world.
Name Current Vs Industry Vs History
Cash-To-Debt 3.41
Equity-to-Asset 0.61
Debt-to-Equity 0.26
Debt-to-EBITDA -0.83
Interest Coverage N/A
N/A
N/A
Piotroski F-Score 3/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 3.48
Distress
Grey
Safe
Beneish M-Score -1.71
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 54.46
9-Day RSI 55.69
14-Day RSI 54.9
6-1 Month Momentum % -29.05
12-1 Month Momentum % -33.62

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 2.32
Quick Ratio 2.09
Cash Ratio 1.75
Days Inventory 313.91
Days Sales Outstanding 43.03
Days Payable 280.55

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -4.5
Shareholder Yield % -0.16

Financials (Next Earnings Date:2024-05-03 Est.)

BGNE's 30-Y Financials
Income Statement Breakdown
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with NAS:BGNE

No Available Data

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

BeiGene Ltd Executives

Details

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 2,458.779
EPS (TTM) ($) -8.58
Beta 0.5
Volatility % 46.02
14-Day RSI 54.9
14-Day ATR ($) 7.81001
20-Day SMA ($) 163.89775
12-1 Month Momentum % -33.62
52-Week Range ($) 132.95 - 272.49
Shares Outstanding (Mil) 104.43

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 3
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

BeiGene Ltd Filings

Filing Date Document Date Form
No Filing Data

BeiGene Ltd Stock Events

Financials Calendars
Event Date Price($)
No Event Data

BeiGene Ltd Frequently Asked Questions

What is BeiGene Ltd(BGNE)'s stock price today?
The current price of BGNE is $168.78. The 52 week high of BGNE is $272.49 and 52 week low is $132.95.
When is next earnings date of BeiGene Ltd(BGNE)?
The next earnings date of BeiGene Ltd(BGNE) is 2024-05-03 Est..
Does BeiGene Ltd(BGNE) pay dividends? If so, how much?
BeiGene Ltd(BGNE) does not pay dividend.

Press Release

Subject Date
No Press Release

Headlines

See More
  • 1
No news.
  • 1